DFDA

Levetiracetam

Treatment for Idiopathic Epilepsy

Typical Dosage: 500-3000 mg daily

Effectiveness
80%
Safety Score
60%
Clinical Trials
4
Participants
60K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
500-3000 mg daily
Time to Effect
Days to weeks
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$500
Side Effect Mgmt:$300
Total Annual:$1,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$15,000/QALY
QALYs Gained
6
Outcome-Based Costs
Cost per Responder
$3,600
Cost per Remission
$5,143
Levetiracetam Outcomes

for Idiopathic Epilepsy

Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+50%
Remission Rate
+35%
Common Side Effects
Somnolence/Fatigue
+18%
Irritability/Agitation
+15%
Dizziness
+12%
Headache
+10%
Anorexia
+8%

Sources:

nih.gov
researchgate.net
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
4 completed trials for Levetiracetam in Idiopathic Epilepsy

Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures

NCT03940326COMPLETEDPHASE4
View Study
103 participants
INTERVENTIONAL
Sari, Iran
Started: Apr 1, 2018

Levetiracetam Versus Valproate in Idiopathic Generalized Epilepsy

NCT06393309COMPLETED
View Study
169 participants
OBSERVATIONAL
Sari, Iran
Started: Sep 3, 2022

Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures

NCT00160550COMPLETEDPHASE3
View Study
154 participants
INTERVENTIONAL
Started: Sep 1, 2001

Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults

NCT00150774COMPLETEDPHASE3
View Study
116 participants
INTERVENTIONAL
Started: Nov 1, 2001